Reduced‐Dose Dabrafenib–Trametinib for <scp>BRAF V600E</scp> –Mutant Lung Adenocarcinoma in a Very Elderly Patient With <scp>ECOG PS</scp> 2
Shun Suyama(Saiseikai Central Hospital), Saeko Takahashi(Saiseikai Central Hospital), Tetsuo Tani(Keio University), Keeya Sunata(Keio University), Shun Shinomiya(Saiseikai Central Hospital), Koyuru Uchibori(Saiseikai Central Hospital)
Cited by 0
Related Papers
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101
<i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
|Cancer Discovery|2024|98
Activation of Tumor-Cell STING Primes NK-Cell Therapy
|Cancer Immunology Research|2022|88
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
|Molecular Cancer Research|2016|73